Legacy Education Sets September Date for Q4 and FY2026 Results

Capricor Therapeutics is under investigation following a 64% single-day stock drop triggered by FDA disclosures regarding statistical analysis changes.

Elevance Health stock climbed to $416.54, trading below intrinsic value estimates despite a weak financial strength rating.

UBS upgrades Thermo Fisher to Buy, raising its price target by 190 dollars to 730, citing sustained organic growth prospects in bioprocessing.

Integra LifeSciences reported flat revenue but raised full-year guidance, while peers like Teleflex showed stronger growth. The stock has declined significantly since the earnings release.

Integra LifeSciences delivered flat revenue in Q2, matching consensus while posting the slowest growth in its peer group. Despite raising full-year guidance, the stock has fallen significantly since the report.

Vertex Pharmaceuticals posted a 12.5% revenue increase, outpacing sector expectations while peers showed mixed results in the latest therapeutics earnings cycle.

Clover Health shares are trading higher following a new Buy initiation from Deutsche Bank, with the stock gapping up to nearly $4.70 on elevated volume. While analysts remain divided on the valuation, recent data highlights significant insider selling by top executives despite the positive technical momentum.

Cooper Companies shares dropped nearly 14% after the firm issued a fourth-quarter earnings forecast well below market expectations and announced it would retain its surgical division.

CooperCompanies shares fell 13.9% after weak Q2 revenue and a decision to retain its surgical unit, prompting a reduction in full-year financial outlooks.

Olema Pharmaceuticals reported a Q2 loss of $0.61 per share, missing analyst consensus. Despite a 3.5% intraday gain, trading volume dropped 92%, and major banks cut price targets.

AtaiBeckley reported a narrower-than-expected Q2 loss, but revenue collapsed over 140% while research expenses more than doubled. Cash reserves remain sufficient for current operations.

Cardinal Health delivered a strong fourth-quarter performance with adjusted earnings per share of $2.91, significantly exceeding market expectations, even as total revenues fell short of consensus targets.

NeuroPace delivered stronger-than-expected second-quarter results, driven by robust growth in its RNS System and a subsequent upward revision to its full-year financial guidance.

Tango Therapeutics reported a wider-than-expected loss as expenses surged and collaboration revenue fell to zero following the conclusion of its Gilead partnership.

Kaplan Fox is investigating Alignment Healthcare for securities law violations, with new details confirming that systematic misclassification of operating expenses inflated Adjusted EBITDA. This accounting irregularity, exposed by a whistleblower complaint, led to a sharp 16.7% decline in the company's share price on July 8, 2026.

CVS Health raises its full-year adjusted operating income target for the Pharmacy segment by $220 million, citing a 7% rise in same-store prescription volumes and improved gross margins.

Roivant Sciences shares climbed following positive clinical results for its pulmonary hypertension therapy, shifting investor focus to the durability of its clinical pipeline and commercial execution capabilities.

Kaplan Fox & Kilsheimer LLP alleges PROCEPT BioRobotics artificially inflated revenue by pulling forward demand through undisclosed discounting.

Kalaris Therapeutics holds $94m in cash with no debt, but rising burn rates threaten its runway.

The Cooper Companies reported record free cash flow and a significant tax benefit, offsetting headwinds from inventory adjustments in its vision care division.

Intuitive Surgical stock trades at a significant discount to its highs while options markets price in substantial volatility, reflecting ongoing uncertainties in procedure growth and instrument costs.

Natera reported new lymphoma data and Japanese regulatory approval, anchoring a valuation based on US$4.2b in projected 2029 revenue.

Monte Rosa Therapeutics (GLUE) received a $50 million payment from Novartis, which has launched a Phase 2a/b trial for MRT-6160 in Sjögren’s disease, shifting clinical costs off the company's balance sheet.

Johnson & Johnson and AbbVie report strong quarterly performance, driven by oncology and immunology growth, while maintaining dividend payouts.

Creo Medical reports 45% H1 revenue growth to £3.2m while reducing operating losses, positioning its endoscopy technology for broader commercial adoption.

Creo Medical has posted a 50% revenue increase to £6m for 2025 while cutting operating costs by 20%, signaling a shift toward commercial scale despite ongoing losses.

Axsome Therapeutics reported second-quarter revenues of $218.4 million, missing consensus estimates despite a 46% year-over-year increase driven by its lead product, Auvelity.

BridgeBio Pharma shares fell 10.7% after Q2 results showed a wider-than-expected loss, even as Attruby sales tripled year-over-year.

Beta Bionics faces a securities class action alleging that the company concealed serious device malfunctions and FDA violations, leading to a significant stock decline after public disclosures in early 2026.

Hims & Hers reported a Q2 adjusted loss of 10 cents per share, missing estimates as operating costs surged faster than revenue growth, prompting a downward revision in analyst consensus despite a raised full-year outlook.

Telix Pharmaceuticals faces a critical FDA deadline for its glioma imaging agent, while Australian regulators ease requirements for maggot debridement therapy and diagnostic firms report lab progress.

DaVita Inc. reported steady treatment volumes and expanded risk-based patient enrollment in the second quarter of 2026, reinforcing its shift toward earlier-stage kidney care while maintaining a hold recommendation from GN stocks/earnings-beat.

Smith & Nephew closed at a new 52-week low on the NYSE following an analyst downgrade and elevated trading volume.

Shares of AdaptHealth dropped 8.6% after announcing a new Chief Financial Officer, a move that follows a recent 39.5% decline driven by slashed financial outlooks and missed revenue targets.

Mineralys Therapeutics issued equity awards to two new non-executive employees under Nasdaq listing rules, adding to its compensation structure for key talent.

United Therapeutics outperformed consensus in Q2, though stock lags peers as Myriad Genetics posts sharp decline.

Intuitive Surgical shares trade near $350, with one-year options pricing a two-thirds probability range of $236 to $519 against a backdrop of slowing US procedure growth.

Veracyte Inc shares climbed to $43.85, trading 12.7% above intrinsic estimates while insiders offload $22 million in stock.

A class action alleges Capricor misled investors regarding its statistical analysis plan for Dermamiocel, leading to a 64% stock drop.

CooperCompanies posted a 2.7% revenue beat in Q1, but issued the weakest full-year guidance among tracked peers, creating a divergence between past performance and future outlook.

Alpha Cognition granted 25,000 stock options to a new non-executive employee under Nasdaq Rule 5635(c)(4), with an exercise price set at the September 8 closing rate.

The Cooper Companies posted a 3.6% earnings surprise in Q3, though the result was tempered by a revenue miss of nearly 3% that highlighted ongoing top-line challenges.

Cooper Companies and Kewaunee Scientific drove significant volatility in Wednesday's after-market session, with both names declining sharply following earnings releases.

CooperCompanies posted flat Q2 revenue of $1.07B, missing estimates by 2.9%, while cutting full-year guidance and seeing a sharp post-earnings stock decline.

Teleflex outpaced peers with strong Q2 growth, while the broader surgical equipment group faces softening forward revenue outlooks.

Rocket Pharmaceuticals reported a quarter with zero revenue but significantly reduced operating expenses, driven by cost cuts in legal and R&D. The company’s cash position expanded sharply due to a regulatory voucher sale, offsetting the lack of product sales.

Theravance Bio posted a profit on sharply lower costs, but core revenue declined 21% year-over-year as it winds down clinical trials.

InnovAge posted fiscal fourth-quarter revenue of $261.95 million, exceeding consensus estimates, while EPS fell short. The stock gapped up following a KeyCorp upgrade, though broader analyst sentiment remains divided.

New clinical data for infigratinib indicates improvements in sleep apnea, ear infections, and body composition for children with achondroplasia, supporting a mid-2027 US launch.

Pacira BioSciences disclosed the grant of stock options and restricted stock units to five new employees under Nasdaq Rule 5635(c)(4), with vesting schedules tied to continued service.

The Cooper Companies will release fiscal third-quarter results on September 9, with consensus expecting modest revenue growth and stable earnings per share.

Former Theranos CEO Elizabeth Holmes is advising a new $18 million blood-testing venture from prison, despite prominent investors declining to participate.

X4 Pharmaceuticals will host a fireside chat at the 2026 Wells Fargo Healthcare Conference to discuss its pipeline and commercial strategy.